PURPOSE: The therapeutic efficacy of a synthetic parasite-derived peptide GK1, an immune response booster, was evaluated in a mouse melanoma model. This melanoma model correlates with human stage IIb melanoma, which is treated with wide surgical excision; a parallel study employing a surgical treatment was carried out as an instructive goal. EXPERIMENTAL DESIGN: C57BL/6 mice were injected subcutaneously in the flank with 2×10(5) B16-F10 murine melanoma cells. When the tumors reached 20 mm3, mice were separated into two different groups; the GK1 group, treated weekly with peritumoral injections of GK1 (10 μg/100 μL of sterile saline solution) and the control group, treated weekly with an antiseptic peritumoral injection of 100 μL of sterile saline solution without further intervention. All mice were monitored daily for clinical appearance, tumor size, and survival. Surgical treatment was performed in parallel when the tumor size was 20 mm3 (group A), 500 mm3 (group B), and >500 mm3 (group C). RESULTS: The GK1 peptide effectively increased the mean survival time by 9.05 days, corresponding to an increase of 42.58%, and significantly delayed tumor growth from day 3 to 12 of treatment. In addition, tumor necrosis was significantly increased (p<0.05) in the treated mice. The overall survival rates obtained with surgical treatment at 6 months were 83.33% for group A, 40% for group B, and 0% for group C, with significant differences (p<0.05) among the groups. CONCLUSIONS: The GK1 peptide demonstrated therapeutic properties in a mouse melanoma model, as treatment resulted in a significant increase in the mean survival time of the treated animals (42.58%). The potential for GK1 to be used as a primary or adjuvant component of chemotherapeutic cocktails for the treatment of experimental and human cancers remains to be determined, and surgical removal remains a challenge for any new experimental treatment of melanoma in mouse models.
PURPOSE: The therapeutic efficacy of a synthetic parasite-derived peptide GK1, an immune response booster, was evaluated in a mousemelanoma model. This melanoma model correlates with human stage IIb melanoma, which is treated with wide surgical excision; a parallel study employing a surgical treatment was carried out as an instructive goal. EXPERIMENTAL DESIGN: C57BL/6 mice were injected subcutaneously in the flank with 2×10(5) B16-F10 murinemelanoma cells. When the tumors reached 20 mm3, mice were separated into two different groups; the GK1 group, treated weekly with peritumoral injections of GK1 (10 μg/100 μL of sterile saline solution) and the control group, treated weekly with an antiseptic peritumoral injection of 100 μL of sterile saline solution without further intervention. All mice were monitored daily for clinical appearance, tumor size, and survival. Surgical treatment was performed in parallel when the tumor size was 20 mm3 (group A), 500 mm3 (group B), and >500 mm3 (group C). RESULTS: The GK1 peptide effectively increased the mean survival time by 9.05 days, corresponding to an increase of 42.58%, and significantly delayed tumor growth from day 3 to 12 of treatment. In addition, tumor necrosis was significantly increased (p<0.05) in the treated mice. The overall survival rates obtained with surgical treatment at 6 months were 83.33% for group A, 40% for group B, and 0% for group C, with significant differences (p<0.05) among the groups. CONCLUSIONS: The GK1 peptide demonstrated therapeutic properties in a mousemelanoma model, as treatment resulted in a significant increase in the mean survival time of the treated animals (42.58%). The potential for GK1 to be used as a primary or adjuvant component of chemotherapeutic cocktails for the treatment of experimental and humancancers remains to be determined, and surgical removal remains a challenge for any new experimental treatment of melanoma in mouse models.
Authors: A Toledo; C Larralde; G Fragoso; G Gevorkian; K Manoutcharian; M Hernández; G Acero; G Rosas; F López-Casillas; C K Garfias; R Vázquez; I Terrazas; E Sciutto Journal: Infect Immun Date: 1999-05 Impact factor: 3.441
Authors: Patrizia Stoitzner; Laura K Green; Jae Y Jung; Kylie M Price; Christoph H Tripp; Bernard Malissen; Adrien Kissenpfennig; Ian F Hermans; Franca Ronchese Journal: J Immunol Date: 2008-02-01 Impact factor: 5.422
Authors: Jasper G van den Boorn; Debby Konijnenberg; Esther P M Tjin; Daisy I Picavet; Nico J Meeuwenoord; Dmitri V Filippov; J P Wietze van der Veen; Jan D Bos; Cornelis J M Melief; Rosalie M Luiten Journal: PLoS One Date: 2010-05-13 Impact factor: 3.240
Authors: R Soiffer; T Lynch; M Mihm; K Jung; C Rhuda; J C Schmollinger; F S Hodi; L Liebster; P Lam; S Mentzer; S Singer; K K Tanabe; A B Cosimi; R Duda; A Sober; A Bhan; J Daley; D Neuberg; G Parry; J Rokovich; L Richards; J Drayer; A Berns; S Clift; L K Cohen; R C Mulligan; G Dranoff Journal: Proc Natl Acad Sci U S A Date: 1998-10-27 Impact factor: 11.205
Authors: Rhiannon R White; Amy H Ponsford; Michael P Weekes; Rachel B Rodrigues; David B Ascher; Marco Mol; Murray E Selkirk; Steven P Gygi; Christopher M Sanderson; Katerina Artavanis-Tsakonas Journal: PLoS Pathog Date: 2016-11-21 Impact factor: 6.823
Authors: Cezary Skobowiat; Allen S W Oak; Tae-Kang Kim; Chuan He Yang; Lawrence M Pfeffer; Robert C Tuckey; Andrzej T Slominski Journal: Oncotarget Date: 2017-02-07